A Promising Frontier in Alzheimer's Treatment

Gupta, Seema MD, MSPH

Clinical Assistant Professor, Department of Family and Community Health, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV

Financial Disclosure: Dr. Stephen Brunton, physician editor, reports he is on the speakers bureau for AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and Sanofi; is a retained consultant for AstraZeneca, Novo Nordisk, and Sanofi; and is a stockholder with Paracrine. Dr. Trushil Shah, author, reports he has received research support and is a consultant for Bayer Pharmaceuticals and United Therapeutics and has received research support from Janssen Research. The relevant financial relationships listed have been mitigated. None of the remaining planners or authors for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Internal Medicine Alert 45(12):p 89-90, June 30, 2023.

SYNOPSIS: In a multicenter, head-to-head trial, donanemab demonstrated superiority over aducanumab for early symptomatic Alzheimer's disease patients.

SOURCE: Salloway S, Lee E, Papka M, et al. TRAILBLAZER-ALZ 4: Topline study results directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer's disease (S26.009). Neurology. Apr 28, 2023. https://bit.ly/3ouxhIX